Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

mHealth Monthly Mashup: Release 17.0 – mobile health insight...

This month’s mashup takes a look at recent mobile health engagement metrics to provide guidance for pharma… We’re no longer interested in mere impressions and conversions,” say the metrics and analytics gurus who now don fancy consultant…

Articles

Enablers of drug innovation could lie in the numbers

Christopher Ehinger discusses the obstacle that clinical-trial recruitment presents to new drug development. Recent developments in the pharmaceutical industry are encouraging drug developers to re-think their strategies toward innovation and...

Articles

The NHS in 2013: a review of 2012 and a look at the year ahe...

Anthony Rowbottom of Clinical Current commences his new series following developments in the NHS. As we start the New Year, it seems like a good opportunity to reflect upon 2012 and look forward to what 2013 will hold. The NHS reforms have…

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital